Shots:

• The FDA’s approval is based on P-III INBUILD study assessing Ofev (150mg- bid) vs PBO in 663 patients with chronic fibrosing ILDs with a progressive phenotype for 52wks. at 153 sites across 15 countries
• The P-III INBUILD study results demonstrated that therapy slowed the loss of pulmonary function by 57% (107ml/yr.) across a range of patients while in patients with IP-like fibrotic pattern on HRCT- Ofev slowed the loss of pulmonary function by 61% (128.2ml/yr.)
• Ofev is a tyrosine kinase inhibitor- approved in 75+ countries for IPF and has received the US FDA’s approval as the first therapy to slow the rate of decline in pulmonary function in patients with SSc-ILD in Sept’2019

Click here ­to­ read full press release/ article | Ref: Boehringer Ingelheim  | Image: News-Times